Currently, clinical guidelines recommend EGFR-tyrosine kinase inhibitors (TKIs) as a first-line therapy for patients with advanced NSCLC (6–8) who are sensitive to EGFR mutations and do not harbor drug resistance genes. This evidence concerns the gene EGFR and non-small cell lung carcinoma.